Sharon Mates, Chairman and CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 182,061 shares at $86.00 ($15.4M) on 2024-12-04, disclosed to the SEC on 2024-12-06.
Scheduled sale ($15.4M) by Chairman and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $85.62 | 27,667 | $2.4M | 15.3% |
| 2 | $85.62 | 27,667 | $2.4M | 15.3% |
| 3 | $86.00 | 23,333 | $2.0M | 13.0% |
| 4 | $84.06 | 50,163 | $4.2M | 27.3% |
| 5 | $84.06 | 50,163 | $4.2M | 27.3% |
| 6 | $84.69 | 1,534 |
| $130K |
| 0.8% |
| 7 | $84.69 | 1,534 | $130K | 0.8% |
| Total | $84.79 avg | 182,061 | $15.4M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |
| ITCI | SELL | 2024-02-27 | $3.1M | — | Filing → |